Ruxolitinib improves steroid-refractory aGVHD across subtypes Presented ByProf. Robert Zeiser, University Hospital Freiburg, Germany TrialPhase 3, REACH2 ConferenceEHA 2020 TypePeer-reviewed article 9 September 2020 09:57